Effectiveness of rectal artesunate as pre-referral treatment for severe malaria in children under 5 years of age: a multi-country observational study.
Case management
Child mortality
Community health worker
Malaria mortality
Malaria treatment
Rectal artesunate
Referral
Severe malaria
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
11 10 2022
11 10 2022
Historique:
received:
04
03
2022
accepted:
24
08
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
13
10
2022
Statut:
epublish
Résumé
To prevent child deaths from severe malaria, early parenteral treatment is essential. Yet, in remote rural areas, accessing facilities offering parenteral antimalarials may be difficult. A randomised controlled trial found pre-referral treatment with rectal artesunate (RAS) to reduce deaths and disability in children who arrived at a referral facility with delay. This study examined the effectiveness of pre-referral RAS treatment implemented through routine procedures of established community-based health care systems. An observational study accompanied the roll-out of RAS in the Democratic Republic of the Congo (DRC), Nigeria and Uganda. Children <5 years of age presenting to a community-based health provider with a positive malaria test and signs of severe malaria were enrolled and followed up during admission and after 28 days to assess their health status and treatment history. The primary outcome was death; covariates of interest included RAS use, referral completion, and post-referral treatment. Post-roll-out, RAS was administered to 88% of patients in DRC, 52% in Nigeria, and 70% in Uganda. The overall case fatality rate (CFR) was 6.7% (135/2011) in DRC, 11.7% (69/589) in Nigeria, and 0.5% (19/3686) in Uganda; 13.8% (865/6286) of patients were sick on day 28. The CFR was higher after RAS roll-out in Nigeria (16.1 vs. 4.2%) and stable in DRC (6.7 vs. 6.6%) and Uganda (0.7 vs. 0.3%). In DRC and Nigeria, children receiving RAS were more likely to die than those not receiving RAS (aOR=3.06, 95% CI 1.35-6.92 and aOR=2.16, 95% CI 1.11-4.21, respectively). Only in Uganda, RAS users were less likely to be dead or sick at follow-up (aOR=0.60, 95% CI 0.45-0.79). Post-referral parenteral antimalarials plus oral artemisinin-based combination therapy (ACT), a proxy for appropriate post-referral treatment, was protective. However, in referral health facilities, ACT was not consistently administered after parenteral treatment (DRC 68.4%, Nigeria 0%, Uganda 70.9%). Implemented at scale to the recommended target group, pre-referral RAS had no beneficial effect on child survival in three highly malaria-endemic settings. RAS is unlikely to reduce malaria deaths unless health system issues such as referral and quality of care at all levels are addressed. The study is registered on ClinicalTrials.gov : NCT03568344.
Sections du résumé
BACKGROUND
To prevent child deaths from severe malaria, early parenteral treatment is essential. Yet, in remote rural areas, accessing facilities offering parenteral antimalarials may be difficult. A randomised controlled trial found pre-referral treatment with rectal artesunate (RAS) to reduce deaths and disability in children who arrived at a referral facility with delay. This study examined the effectiveness of pre-referral RAS treatment implemented through routine procedures of established community-based health care systems.
METHODS
An observational study accompanied the roll-out of RAS in the Democratic Republic of the Congo (DRC), Nigeria and Uganda. Children <5 years of age presenting to a community-based health provider with a positive malaria test and signs of severe malaria were enrolled and followed up during admission and after 28 days to assess their health status and treatment history. The primary outcome was death; covariates of interest included RAS use, referral completion, and post-referral treatment.
RESULTS
Post-roll-out, RAS was administered to 88% of patients in DRC, 52% in Nigeria, and 70% in Uganda. The overall case fatality rate (CFR) was 6.7% (135/2011) in DRC, 11.7% (69/589) in Nigeria, and 0.5% (19/3686) in Uganda; 13.8% (865/6286) of patients were sick on day 28. The CFR was higher after RAS roll-out in Nigeria (16.1 vs. 4.2%) and stable in DRC (6.7 vs. 6.6%) and Uganda (0.7 vs. 0.3%). In DRC and Nigeria, children receiving RAS were more likely to die than those not receiving RAS (aOR=3.06, 95% CI 1.35-6.92 and aOR=2.16, 95% CI 1.11-4.21, respectively). Only in Uganda, RAS users were less likely to be dead or sick at follow-up (aOR=0.60, 95% CI 0.45-0.79). Post-referral parenteral antimalarials plus oral artemisinin-based combination therapy (ACT), a proxy for appropriate post-referral treatment, was protective. However, in referral health facilities, ACT was not consistently administered after parenteral treatment (DRC 68.4%, Nigeria 0%, Uganda 70.9%).
CONCLUSIONS
Implemented at scale to the recommended target group, pre-referral RAS had no beneficial effect on child survival in three highly malaria-endemic settings. RAS is unlikely to reduce malaria deaths unless health system issues such as referral and quality of care at all levels are addressed.
TRIAL REGISTRATION
The study is registered on ClinicalTrials.gov : NCT03568344.
Identifiants
pubmed: 36217159
doi: 10.1186/s12916-022-02541-8
pii: 10.1186/s12916-022-02541-8
pmc: PMC9550309
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Artesunate
60W3249T9M
Banques de données
ClinicalTrials.gov
['NCT03568344']
Types de publication
Journal Article
Observational Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
343Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
World Health Organization. World Malaria Report 2021. Geneva: World Health Organization; 2021.
doi: 10.30875/6c551ba0-en
World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
Young M, Wolfheim C, Marsh DR, Hammamy D. World Health Organization/United Nations Children's Fund Joint Statement on Integrated Community Case Management: An Equity-Focused Strategy to Improve Access to Essential Treatment Services for Children. Am Soc Trop Med Hyg. 2012;87(5_Suppl):6–10.
doi: 10.4269/ajtmh.2012.12-0221
Coetzer RH, Adeola AM. Assessing the Correlation between Malaria Case Mortality Rates and Access to Health Facilities in the Malaria Region of Vhembe District, South Africa. J Environ Public Health. 2020;2020:8973739.
doi: 10.1155/2020/8973739
pubmed: 33343669
pmcid: 7732409
Karra M, Fink G, Canning D. Facility distance and child mortality: a multi-country study of health facility access, service utilization, and child health outcomes. Int J Epidemiol. 2017;46(3):817–26.
pubmed: 27185809
de Carvalho LP, Kreidenweiss A, Held J. The preclinical discovery and development of rectal artesunate for the treatment of malaria in young children: a review of the evidence. Expert Opin Drug Discov. 2021;16(1):13–22.
doi: 10.1080/17460441.2020.1804357
pubmed: 32921162
Gomes MF, Faiz MA, Gyapong JO, Warsame M, Agbenyega T, Babiker A, et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet. 2009;373(9663):557–66.
doi: 10.1016/S0140-6736(08)61734-1
pubmed: 19059639
pmcid: 2646124
Okebe J, Eisenhut M. Pre-referral rectal artesunate for severe malaria. Cochrane Database Syst Rev. 2014;2014(5):Cd009964.
pubmed: 24869943
pmcid: 4463986
von Seidlein L, Deen JL. Pre-referral rectal artesunate in severe malaria. Lancet. 2009;373(9663):522–3.
doi: 10.1016/S0140-6736(08)61735-3
Obrist B, Iteba N, Lengeler C, Makemba A, Mshana C, Nathan R, et al. Access to health care in contexts of livelihood insecurity: a framework for analysis and action. PLoS Med. 2007;4(10):e308.
doi: 10.1371/journal.pmed.0040308
pubmed: 17958467
pmcid: 2039761
World Health Organization. WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control). Geneva: World Health Organization; 2021.
CARAMAL Project: Rectal Artesunate Landscaping Assessment Report. Geneva: Unitaid; 2018. Available at: https://www.severemalaria.org/resources/rectal-artesunate-landscaping-assessment-report
World Health Organization. Global technical strategy for malaria 2016-2030. Geneva: World Health Organization; 2015.
Lengeler C, Burri C, Awor P, Athieno P, Kimera J, Tumukunde G, et al. Community access to rectal artesunate for malaria (CARAMAL): A large-scale observational implementation study in the Democratic Republic of the Congo, Nigeria and Uganda. PLOS Global Public Health. 2022;2(9): e0000464
Ferrari G, Ntuku HM, Burri C, Tshefu AK, Duparc S, Hugo P, et al. An operational comparative study of quinine and artesunate for the treatment of severe malaria in hospitals and health centres in the Democratic Republic of Congo: the MATIAS study. Malar J. 2015;14:226.
doi: 10.1186/s12936-015-0732-1
pubmed: 26024661
pmcid: 4455055
Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647–57.
doi: 10.1016/S0140-6736(10)61924-1
pubmed: 21062666
pmcid: 3033534
Fleiss J, Levin B, Paik M. Statistical Methods for Rates and Proportions. 3rd ed. New York: Wiley; 2003.
doi: 10.1002/0471445428
Idro R, Ndiritu M, Ogutu B, Mithwani S, Maitland K, Berkley J, et al. Burden, features, and outcome of neurological involvement in Acute Falciparum Malaria in Kenyan Children. JAMA. 2007;297(20):2232–40.
doi: 10.1001/jama.297.20.2232
pubmed: 17519413
pmcid: 2676709
Brunner NC, Omoluabi E, Awor P, Okitawutshu J, Tshefu Kitoto A, Signorell A, et al. Prereferral rectal artesunate and referral completion among children with suspected severe malaria in the Democratic Republic of the Congo, Nigeria and Uganda. BMJ Glob Health. 2022;7:e008346.
doi: 10.1136/bmjgh-2021-008346
pubmed: 35580913
pmcid: 9114942
Signorell A, Awor P, Okitawutshu J, Tshefu A, Omoluabi E, Hetzel MW, et al. Health worker compliance with severe malaria treatment guidelines in the context of implementing pre-referral rectal artesunate: an operational study in three high burden countries. medRxiv. 2021;2021.11.26.21266917. https://doi.org/10.1101/2021.11.26.21266917 .
Dalrymple U, Arambepola R, Gething PW, Cameron E. How long do rapid diagnostic tests remain positive after anti-malarial treatment? Malar J. 2018;17(1):228.
doi: 10.1186/s12936-018-2371-9
pubmed: 29884184
pmcid: 5994115
Hirji KF, Premji ZG. Pre-referral rectal artesunate in severe malaria: flawed trial. Trials. 2011;12:188.
doi: 10.1186/1745-6215-12-188
pubmed: 21824389
pmcid: 3171715
Green C, Quigley P, Kureya T, Barber C, Chizema E, Moonga H, et al. Use of rectal artesunate for severe malaria at the community level, Zambia. Bull World Health Organ. 2019;97(12):810–7.
doi: 10.2471/BLT.19.231506
pubmed: 31819289
pmcid: 6883271
Phiri TB, Kaunda-Khangamwa BN, Bauleni A, Chimuna T, Melody D, Kalengamaliro H, et al. Feasibility, acceptability and impact of integrating malaria rapid diagnostic tests and pre-referral rectal artesunate into the integrated community case management programme. A pilot study in Mchinji district, Malawi. Malar J. 2016;15:177.
doi: 10.1186/s12936-016-1237-2
pubmed: 27000034
pmcid: 4802711
Warsame M, Gyapong M, Mpeka B, Rodrigues A, Singlovic J, Babiker A, et al. Pre-referral Rectal Artesunate Treatment by Community-Based Treatment Providers in Ghana, Guinea-Bissau, Tanzania, and Uganda (Study 18): A Cluster-Randomized Trial. Clin Infect Dis. 2016;63(suppl 5):S312–21.
doi: 10.1093/cid/ciw631
pubmed: 27941110
pmcid: 5146703
Awad MI, Alkadru AMY, Behrens RH, Baraka OZ, Eltayeb IB. Descriptive study on the efficacy and safety of artesunate suppository in combination with other antimalarials in the treatment of severe malaria in Sudan. Am J Trop Med Hyg. 2003;68(2):153–8.
doi: 10.4269/ajtmh.2003.68.153
pubmed: 12641404
Gomes M, Ribeiro I, Warsame M, Karunajeewa H, Petzold M. Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies. BMC Infect Dis. 2008;8:39.
doi: 10.1186/1471-2334-8-39
pubmed: 18373841
pmcid: 2364627
Lee TT, Omoluabi E, Ayodeji K, Yusuf O, Okon C, Brunner NC, et al. Treatment-seeking for children with suspected severe malaria attending community health workers and primary health centres in Adamawa State, Nigeria. medRxiv. 2021;2021.12.01.21267130. https://doi.org/10.1101/2021.12.01.21267130 .
Agbonlahor DE, Akpede GO, Happi CT, Tomori O. 52 Years of lassa fever outbreaks in Nigeria, 1969-2020: an epidemiologic analysis of the temporal and spatial trends. Am J Trop Med Hyg. 2021;105(4):974–85.
Nigeria Centre for Disease Control: Lassa Fever Situation Report, Epi Week 19: 04-10 May 2020. Abuja: Nigeria Centre for Disease Control; 2020. Available at: https://reliefweb.int/report/nigeria/ncdc-lassa-fever-situation-report-epi-week-19-04-10-may-2020 .
Akpede GO, Sykes RM, Abiodun PO. Convulsions with malaria: febrile or indicative of cerebral involvement? J Trop Pediatr. 1993;39(6):350–5.
doi: 10.1093/tropej/39.6.350
pubmed: 8133557
Lambiris M, Ndongala G, Ssempala R, Balogun V, Musiitwa M, Kagwire F, et al. Real world costs and barriers to the successful implementation of rectal artesunate as pre-referral treatment for severe malaria in Sub-Saharan Africa. medRxiv. 2022;2022.05.24.22275488. https://doi.org/10.1101/2022.05.24.22275488 .
Strachan CE, Nuwa A, Muhangi D, Okui AP, Helinski MEH, Tibenderana JK. Community understanding of the concept of pre-referral treatment and how this impacts on referral related decision-making following the provision of rectal artesunate: a qualitative study in western Uganda. BMC Health Serv Res. 2018;18(1):470.
doi: 10.1186/s12913-018-3209-4
pubmed: 29914478
pmcid: 6006771
Simba DO, Kakoko DC, Warsame M, Premji Z, Gomes MF, Tomson G, et al. Understanding caretakers' dilemma in deciding whether or not to adhere with referral advice after pre-referral treatment with rectal artesunate. Malar J. 2010;9:123.
doi: 10.1186/1475-2875-9-123
pubmed: 20459853
pmcid: 2877062
Barnes KI, Mwenechanya J, Tembo M, McIlleron H, Folb PPI, Ribeiro I, et al. Efficacy of rectal artesunate compared with parenteral quinine in initial treatment of moderately severe malaria in African children and adults: a randomised study. Lancet. 2004;363(9421):1598–605.
doi: 10.1016/S0140-6736(04)16203-X
pubmed: 15145633
Ndwiga L, Kimenyi KM, Wamae K, Osoti V, Akinyi M, Omedo I, et al. A review of the frequencies of Plasmodium falciparum Kelch 13 artemisinin resistance mutations in Africa. Int J Parasitol Drugs Drug Resist. 2021;16:155–61.
doi: 10.1016/j.ijpddr.2021.06.001
pubmed: 34146993
pmcid: 8219943
Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of Artemisinin-Resistant Malaria in Africa. N Engl J Med. 2021;385(13):1163–71.
doi: 10.1056/NEJMoa2101746
pubmed: 34551228
World Health Organization: WHO recommends groundbreaking malaria vaccine for children at risk. Geneva; 2021. Available at: https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk .
Karim A, Cobos Munoz D, Mausezahl D, de Savigny D. A systems approach to assessing complexity in health interventions: an effectiveness decay model for integrated community case management. Global Health Action. 2020;13(1):1794106.
doi: 10.1080/16549716.2020.1794106
pubmed: 32772891
pmcid: 7480477
Hetzel MW, Okitawutshu J, Tshefu A, Omoluabi E, Awor P, Signorell A, et al. Dataset for: Effectiveness of rectal artesunate as pre-referral treatment for severe malaria in children under 5 years of age: a multi-country observational study. Zenodo. 2022. https://doi.org/10.5281/zenodo.5548261 .